Diagnostics consultation document

The National Institute for Health and Care Excellence (NICE) is producing guidance on using FibroScan in primary or community care in the NHS in England. The diagnostics advisory committee has considered the evidence and the views of clinical and patient experts.

This document has been prepared for public consultation. It summarises the evidence and views that have been considered, and sets out the recommendations made by the committee. NICE invites comments from registered stakeholders, healthcare professionals and the public. This document should be read along with the evidence (the company clinical and economic submissions, EAG reports, overview).

How to comment

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments.

We have a new way of making comments on this consultation. You must make your comments directly onto the online version of the consultation document. When you go into the document you will find instructions on how to use the new commenting software.  You can also review and edit your comments before you submit them.

You can download a PDF version of the consultation document, but you can only make comments on the online version.

 Consultation documents

  • The documents from the first consultation are available on the NICE website. 

 Revised closing date for comments: 8 December 2022

 About the consultation

The advisory committee is interested in receiving comments on the following:

  • Has all of the relevant evidence been taken into account?
  • Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
  • Are the recommendations sound, and a suitable basis for guidance to the NHS?

 Equality issues

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the recommendations may need changing to meet these aims. In particular, please tell us if the recommendations:

  • could have a different effect on people protected by the equality legislation than on the wider population, for example by making it more difficult in practice for a specific group to access the technology
  • could have any adverse effect on people with a particular disability or disabilities.

 Please provide any relevant information or data you have about such effects and how they could be avoided or reduced.

Note that this document is not NICE's final guidance on FibroScan in primary or community care. The recommendations in section 1 may change after consultation.

 

Find out more

 

For further details, see the diagnostics assessment programme manual

 

If you have any problems, contact diagnostics@nice.org.uk